Kymera Therapeutics, Inc. (KYMR) reported a second-quarter loss of 62 cents per share for 2026, better than the Zacks Consensus Estimate of a loss of 64 cents and an improvement from a loss of 95 cents in the same quarter last year. Revenues surged to $65 million from $11.5 million in the year-ago period, significantly surpassing the consensus estimate of $39 million.
Key revenue contributors included a $45 million option exercise fee from Gilead Sciences, Inc. (GILD) and a $20 million milestone payment following Sanofi (SNY)‘s initiation of a phase I study for KT-485. Kymera’s research and development expenses rose sharply by 52.4% year over year to $119.48 million due to increased investments across several programs. As of June 30, 2026, the company maintained $1.50 billion in cash and marketable securities, projected to fund operations through 2029.
Kymera has accelerated the enrollment timeline for its KT-621 program, now targeting top-line data by year-end 2026, with phase III trials anticipated to start by mid-2027. This investigational drug aims to treat type II inflammatory diseases, while ongoing and planned studies for KT-579, targeting IRF5, are set for results in late 2026.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
